We are live on ! Find out more
AA

ALPS Advisors Portfolio holdings

AUM $21.3B
1-Year Est. Return 21.71%
This Fund
S&P 500
This Quarter Est. Return
+7.47%
1 Year Est. Return
+21.71%
3 Year Est. Return
+77.63%
5 Year Est. Return
+121.1%
10 Year Est. Return
+198.29%
AUM
$15.3B
AUM Growth
+$2.76B
Cap. Flow
+$1.92B
Cap. Flow %
12.55%
Top 10 Hldgs %
45.98%
Holding
1,005
New
144
Increased
321
Reduced
458
Closed
80

Sector Composition

Rank Sector Weight
1 Energy 54.25%
2 Financials 6.56%
3 Healthcare 3.56%
4 Consumer Discretionary 2.58%
5 Industrials 2.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NFLX icon
176
Netflix
NFLX
$292B
$4.61M 0.03%
117,730
-14,430
-11% -$492K
ONCE
177
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$4.45M 0.03%
53,708
+4,076
+8% +$315K
MSFT icon
178
Microsoft
MSFT
$2.84T
$4.42M 0.03%
44,802
+2,198
+5% +$213K
FWONA icon
179
Liberty Media Series A
FWONA
$22.3B
$4.39M 0.03%
129,958
+5,719
+5% +$165K
AU icon
180
AngloGold Ashanti
AU
$40.3B
$4.39M 0.03%
534,346
-1,110
-0.2% -$9.71K
PAAS icon
181
Pan American Silver
PAAS
$18.6B
$4.36M 0.03%
243,615
+136,558
+128% +$2.35M
VB icon
182
Vanguard Small-Cap ETF
VB
$79.5B
$4.18M 0.03%
26,885
-2,335
-8% -$357K
GFI icon
183
Gold Fields
GFI
$29.2B
$4.14M 0.03%
1,160,387
-58,625
-5% -$219K
EBS icon
184
Emergent Biosolutions
EBS
$375M
$4.07M 0.03%
80,540
+5,180
+7% +$270K
HRTX icon
185
Heron Therapeutics
HRTX
$86.3M
$4.03M 0.03%
103,723
+17,646
+21% +$562K
HZNP
186
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$3.95M 0.03%
238,324
+18,517
+8% +$282K
SA
187
Seabridge Gold
SA
$2.8B
$3.93M 0.03%
352,370
-94,589
-21% -$1.02M
MUX icon
188
McEwen Inc
MUX
$1.03B
$3.88M 0.03%
187,446
-28,488
-13% -$608K
HALO icon
189
Halozyme
HALO
$9.72B
$3.87M 0.03%
229,566
+14,709
+7% +$278K
AERI
190
DELISTED
Aerie Pharmaceuticals
AERI
$3.85M 0.03%
56,967
+6,411
+13% +$359K
ENTA icon
191
Enanta Pharmaceuticals
ENTA
$372M
$3.84M 0.03%
33,135
+1,872
+6% +$187K
IRWD icon
192
Ironwood Pharmaceuticals
IRWD
$611M
$3.8M 0.02%
237,483
+20,665
+10% +$306K
ICPT
193
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$3.56M 0.02%
+42,454
New +$3.11M
ASND icon
194
Ascendis Pharma A/S
ASND
$16.7B
$3.55M 0.02%
53,324
+4,549
+9% +$299K
BAC icon
195
Bank of America
BAC
$435B
$3.46M 0.02%
122,874
+40,583
+49% +$1.21M
GBT
196
DELISTED
Global Blood Therapeutics, Inc.
GBT
$3.38M 0.02%
74,716
+13,010
+21% +$592K
XLRN
197
DELISTED
Acceleron Pharma
XLRN
$3.22M 0.02%
66,432
+5,762
+9% +$210K
PAGP icon
198
Plains GP Holdings
PAGP
$5.23B
$3.19M 0.02%
133,282
-4,314
-3% -$106K
ARNA
199
DELISTED
Arena Pharmaceuticals Inc
ARNA
$3.1M 0.02%
70,994
+18,392
+35% +$790K
AKRX
200
DELISTED
Akorn Inc
AKRX
$3M 0.02%
180,583
+12,584
+7% +$193K

Similar funds

ALPS Advisors's Q2 2018 Portfolio in Review

As of Q2 2018, ALPS Advisors held 1,005 positions worth $15.3B, up 22% from $12.6B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

ALPS Advisors deployed $1.92B of net new capital in Q2 2018, opening 144 new positions and adding to 321 existing holdings. Its largest new stake was Berkshire Hathaway Class A: 1,144 shares worth $323M.

By sector, the portfolio is most concentrated in Energy at 54% of assets, down from 56% a quarter earlier, followed by Financials and Healthcare.

On the sell side, the largest reduction was Dominion Energy Midstream Ptr LP, an estimated $55.1M trimmed.

  • ALPS Advisors's largest Q2 2018 buy was Berkshire Hathaway Class A: 1,144 shares worth $323M.
  • ALPS Advisors added most to JPMorgan Chase in Q2 2018, an estimated $113M increase.
  • ALPS Advisors's biggest Q2 2018 reduction was Dominion Energy Midstream Ptr LP, cutting an estimated $55.1M.
  • ALPS Advisors fully exited BeOne Medicines Ltd in Q2 2018, selling an estimated $9.35M.
  • ALPS Advisors's ten largest holdings make up 46% of its $15.3B portfolio in Q2 2018.
  • ALPS Advisors opened 144 new positions and closed 80 in Q2 2018.
  • ALPS Advisors's portfolio value rose 22% quarter-over-quarter to $15.3B.

Based on ALPS Advisors's 13F filing for Q2 2018, filed 25 Jul 2018.